Shares of Celgene Corporation (NASDAQ:CELG) ended Friday session in red amid volatile trading. The shares closed down -0.88 points or -0.83% at $105.49 with 3.27 million shares getting traded. Post opening the session at $107.00, the shares hit an intraday low of $105.26 and an intraday high of $107.00 and the price vacillated in this range throughout the day. The company has a market cap of $81.48 billion and the numbers of outstanding shares have been calculated to be 775.11 million shares.
Celgene Corporation (CELG) plans to present at two upcoming investor conferences and at an R&D deep dive in September where Celgene management will provide an overview of the Company. The conferences and R&D deep dive will be webcast live and the webcasts will be available in the Investor Relations section of the Company’s website at www.celgene.com.
Wednesday, September 7, 2016, Celgene will present at the Citi 11th Annual Biotech Conference in Boston at 12 noon ET
Monday, September 12, 2016, Celgene will present at the Morgan Stanley Global Healthcare Unplugged Conference in New York City at 2:50 pm ET
Thursday, September 29, 2016, Celgene will webcast an R&D Deep Dive on Protein Homeostasis beginning at 1:30pm ET. The webcast is expected to conclude at 5pm ET.
Shares of Envision Healthcare Holdings Inc (NYSE:EVHC) ended Friday session in green amid volatile trading. The shares closed up +0.73 points or 3.40% at $22.18 with 5.29 million shares getting traded. Post opening the session at $21.55, the shares hit an intraday low of $21.44 and an intraday high of $22.22 and the price vacillated in this range throughout the day. The company has a market cap of $4.15 billion and the numbers of outstanding shares have been calculated to be 187.17 million shares.
Envision Healthcare Holdings Inc (EVHC) on August 4, 2016 reported results from operations for the three months and six months ended June 30, 2016.
- Net revenue of $1.64 billion, an increase of 21.2%;
- Net income of $28.4 million compares with $52.4 million;
- Adjusted EBITDA of $172.0 million compares with $162.8 million;
- GAAP diluted earnings per share (EPS) was $0.15 and compares with $0.27; and
- Adjusted diluted EPS was $0.34 and compares with $0.37.
“Our results for the second quarter of 2016 reflect solid operating performance for our EmCare hospital-based physician services and legacy AMR operations,” said William A. Sanger, chairman, president and chief executive officer. “Our AMR financial results were impacted by investments made in certain Rural/Metro markets to meet customer service expectations and establish our position as valued partners in these communities. In addition, we experienced a delay in the expected earnings contribution from Evolution Health’s recently launched Florida health plan contract. We remain confident that we will achieve our targeted financial performance for both Rural/Metro and Evolution’s health plan contract during the first half of 2017. Our 2016 outlook is being updated to reflect the timing of expected improvements.”